SCHEMBL24847849

SCHEMBL24847849

COC(OC)C1CCN(c2ccc(F)c(Br)c2)CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 5/20 0.38
DPP8 Q6V1X1 5/20 0.38
DPP9 Q86TI2 5/20 0.38
DPP7 Q9UHL4 5/20 0.38
KDM4E B2RXH2 2/20 0.37
IDO1 P14902 1/20 0.37
MCOLN2 Q8IZK6 1/20 0.36
RXRA P19793 5/20 0.36
GRIN1 Q05586 5/20 0.36
GRIN2B Q13224 5/20 0.36
ALDH1A1 P00352 1/20 0.35
TSHR P16473 1/20 0.35
MEN1 O00255 1/20 0.35
LMNA P02545 1/20 0.35
MAPT P10636 1/20 0.35
KMT2A Q03164 1/20 0.35
MAPK1 P28482 1/20 0.34
CCR1 P32246 1/20 0.33
ACACB O00763 1/20 0.33
HIF1A Q16665 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20211889 0.89 DPP4 (0.36) DPP4DPP8DPP9DPP7MCOLN2
SCHEMBL29683460 0.89 DPP4 (0.36) DPP4DPP8DPP9DPP7MCOLN2
SCHEMBL31289261 0.82 CCR1 (0.41) DPP4DPP8DPP9DPP7MCOLN2
SCHEMBL30769237 0.81 GAA (0.39) DPP4RXRAALDH1A1TSHRMEN1
SCHEMBL31111891 0.81 DPP4 (0.36) DPP4DPP8DPP9DPP7MCOLN2
SCHEMBL31289233 0.80 ALDH1A1 (0.44) DPP4DPP8DPP9DPP7KDM4E
SCHEMBL30768476 0.80 MAPT (0.42) DPP4ALDH1A1MEN1LMNAMAPT
SCHEMBL29927711 0.80 ALDH1A1 (0.47) KDM4EALDH1A1MEN1LMNAMAPT
SCHEMBL25134014 0.80 ALDH1A1 (0.47) KDM4EALDH1A1MEN1LMNAMAPT
SCHEMBL20231014 0.79 IGF1R (0.42) MEN1LMNAMAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250179075-A1 MK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-06-05 US disclosed
US-20230135894-A1 MK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-05-04 US disclosed
US-20230135894-A1 MK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-05-04 US disclosed
US-20230135894-A1 MK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-05-04 US disclosed
WO-2023278759-A1 MK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-01-05 WO disclosed
WO-2023278759-A1 MK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230135894-A1 MK2 DEGRADERS AND USES THEREOF MKNK2, MKRN3, DUS2 DPP4 1766/4885DPP8 1958/4885DPP9 1860/4885
US-20250179075-A1 MK2 DEGRADERS AND USES THEREOF MKNK2, MKRN3, DUS2 DPP4 1766/4885DPP8 1958/4885DPP9 1860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.